The location of TnlO genes encoding tetracycline resistance and its regulation was determined by analyzing the properties of recombinant plasmids carrying partial HpaI digestion products of A::TnlO transducing phage deoxyribonucleic acid. Within a 2,700-base pair region are encoded tetracycline resistance, the structural gene (tet) for a tetracycline-inducible polypeptide, and the regulatory elements for the induction of both the resistance phenotype and the polypeptide. Fusion of different sequences to an HpaI site in the tet gene alters the molecular weight and stability of the polypeptide as well as the tetracycline resistance phenotype of strains producing fusion polypeptides. These results indicate the orientation of the tet gene and support the conclusion that the tet polypeptide is required for tetracycline resistance. A Hincd cleavage site immediately upstream from the tet gene is protected by ribonucleic acid polymerase, but only in the absence of ribonucleotide triphosphates. The possibility that tet transcription is initiated at this site is discussed.
Tetracycline resistance specified by the R-factor R100 (also called R222 and NR1) is carried by a 9,300-base pair-long transposon termed TnlO (16, 30) . The mechanism of resistance to tetracycline involves an inhibition of uptake, rather than degradation or modification, of the drug (12, 20) . Uptake of tetracycline by sensitive Escherichia coli cells involves at least two independent transport systems, one active and one passive (26) ; both systems are depressed in tetracycline-resistant cells (20) . In addition to uptake inhibition, resistant cells are reported to possess an internal (intracellular) mechanism for inhibition of tetracycline activity (20) . Thus, a combination of decreased transport and decreased sensitivity of intracellular components seems to be responsible for the resistance mediated by R100. Further, these observations suggest that several gene products may be involved in tetracycline resistance.
The expression of tetracycline resistance is regulated in that pretreatment of resistant cells with subinhibitory levels of the drug increases the level of resistance (12) . Levy and McMurry (19) and Levy et al. (21) have reported the Rfactor-directed synthesis of a tetracycline-inducible membrane-associated polypeptide ("TET" protein) and suggested that this protein is responsible for tetracycline resistance. That the regulation of tetracycline resistance is mediated, at least in part, by a repressor has been suggested by Yang et al. (35) , who reported the partial purification from R222-containing cells of an inhibitor of TET protein synthesis in vitro. This inhibition was reversible by the addition of tetracycline.
In this communication we described experiments which examine the ability of recombinant plasmids carrying TnlO deletions affecting tetracycline resistance to synthesize polypeptides in E. coli minicells. These studies demonstrate that the TET protein is indeed encoded by TnlO and is necessary for tetracycline resistance. The gene encoding the TET protein (tet) was precisely located within TnlO, and its direction of transcription was determined. In addition, the probable location of the tet promoter region is inferred from RNA polymerase binding and protection experiments.
MATERIALS AND METHODS Phage and bacterial strains. The A::Tn1O phage used here is A::TnlO(l), described previously (14) . Strain C600 rK_ mK (from J. Davies) is thr leu lac B1-and is defective in the K-12 restriction and modification system. X984 (from R. Curtiss) is a minicellproducing strain of E. coli that is met ilv his ade pdx. DNA from Akan3 (6) and R-factors JR225 and NR79 were kindly provided by J. Davies. Plasmid R100 (also known as NR1 or R222) was obtained from R. Rownd and was introduced into C600 rK mK and X984 by conjugation. 705 706 JORGENSEN AND REZNIKOFF DNA preparation and restriction enzyme digestion. Phage DNA was prepared for restriction enzyme treatment by phenol extraction as described by Barnes et al. (4) . Plasmid (17) and electrophoresed at 35 mA for 5 to 6 h on a constant current power supply. Gels were dried by heating under a vacuum at 700C and were autoradiographed at room temperature using Kodak X-Omat R film. Molecular weight markers used here were [3S]methionine-labeled proteins from purified bacteriophage A particles which were prepared for electrophoresis by mixing with unlabeled cells and heating to 900C in sample buffer.
RNA polymerase "protection experiment." Four micrograms of E. coli RNA polymerase (4 mg/ ml; a gift from S. Rothstein and L. Maquat) was incubated with 1 ,ug of pRT61 DNA at 37°C for 30 min in buffer PBBX + 0.1 M KCI (13) to allow formation of stable polymerase-DNA complexes. Six units of HincII was then added, and incubation was continued for 60 min. Two controls were treated identically except (i) one received no RNA polymerase and (ii) one was made 400 ,uM in the four ribonucleoside triphosphates immediately prior to addition of HincIl. After HincII treatment, each mixture was phenol and ether extracted and subjected to electrophoresis on 8% polyacrylamide gels as described above.
RESULTS
Construction and characterization of deletions of TnlO defining the tetracycline resistance genes. In an earlier communication (14) we described the determination of a restriction enzyme cleavage map for TnlO (Fig. 1) (4-kilobase), amplifiable, multicopy plasmid with a single HincII cleavage site (10) . HincII (GTPy4PuAC) recognizes both HpaI (GTT4AAC) and SalI (GITCGAC) cleavage sites. The plasmid, pVH51, is not cut by either HpaI or Sail. Therefore, the sequence of the HincII site on the plasmid is GTC4AAC, and ligation of a HpaI fragment at this site reconstitutes two HincII sites but only one HpaI site.
To choose among plasmids for further study, three criteria were used: (i) that all HpaI fragments cloned in each plasmid carry TnlO DNA (i.e., no X HpaI fragments are found in the plasmid unless that fragment also carries TnlO DNA); (ii) that in each recombinant plasmid HincII cleavage sites have been reconstituted at the junctions of TnlO and pVH51 DNA (i.e., no exonucleolytic degradation has occurred prior to ligation); and (iii) that each plasmid results from an independent ligation event.
Of 25 tetracycline-resistant clones examined, 8 met these criteria, established by HincII and HpaI restriction analysis of their plasmid DNAs (HpaI restriction patterns are shown in Fig. 2 ). The regions of TnlO carried in these eight recombinant plasmids are illustrated in Fig. 3 . The smallest plasmid, pRT29, carries only HpaI fragment 2025, indicating that this fragment alone is sufficient for generating the tetracycline resistance phenotype.
With the exception of pRT29, each plasmid carries two or more HpaI fragments. The simplest way in which these plasmids could have been formed is by ligation of a single incomplete HpaI cleavage product to the HincII-cleaved pVH51 molecule. An alternate route is by ligation of two HpaI cleavage products (completely or incompletely digested by HpaI) to the vector.
The latter reaction would result in joining two fragments which do not adjoin in TnlO, or which do adjoin in the original sequence but in such a manner that the orientation of the fragments is reversed as compared with the original orientation (i.e., the "wrong" ends of the molecules are joined), or both. pRT4 is an obvious example of the former possibility (HpaI fragments 2025 and 3000 are joined in this plasmid). Establishment°c of the map order and relative orientations of neighboring fragments in each of these seven plasmids was accomplished by double digestion experiments (data not shown) with restriction enzymes having only one cleavage site in the cloned region (e.g., BamHI, XbaI, EcoRI, Bgll, AvaI, and PstI; see map at the top of Fig. 3 Fig. 4 for a map of pRT29). Thus the nucleotide sequence of the pVH51 HincII site, reading from the EcoRI site to the KpnI site, must be GTCJAAC. This information, together with the comparisons of HincII and HpaI restriction patterns described earlier, allows us to orient the insertions of the other seven plasmids. In Fig. 3 , that end of an inserted segment of DNA at which the reconstituted HpaI cleavage site lies is indicated by an unlabeled arrow. Interesting examples are pRT1 and pRT24, in which the same cloned fragments lie in opposite orientations relative to pVH51 sequences.
Effect ofdeletions in TnlO on tetracycline resistance. Table 1 presents a comparison of tetracycline resistance levels conferred on E. coli C600 cells by the R-factor R100, a X::TnlO prophage, and multicopy recombinant plasmids carrying various portions of TnlO. Resistance levels are reported here as the tetracycline concentration at which the efficiency of plating for a given strain is 50% (EOP5o) and were measured both before and after treatment with subinhibitory levels of tetracycline. Since Table 1 on the basis of the induced EOP50 levels. Class I plasmids given EOP50 values of 90 to 105 ,ig/ml for induced cells (experiment 1). This class includes plasmids pRT3, pRT24, and pRT1, as well as pRT61, a recombinant plasmid which carries the entire TnlO transposon (the construction of pRT61 has been described elsewhere [14] ). Inspection of the physical maps of class I plasmids indicates that sequences in TnlO to the "left" ofHpaI fragment 2025 (see Fig. 3 ) do not contribute to tetracycline resistance. Also, from the fact that the insertions in pRT1 and pRT24 are identical but in opposite orientations relative to pVH51, we conclude that the orientation of this insertion has no effect on the expression of tetracycline resistance in these plasmids. Plasmids pRT2, pRT4, and pRT11 comprise class II; these plasmids confer resistance to much higher levels of tetracycline than do class I plasmids (experiments 1 and 3, Table  1 ). Class II plasmids pRT2 and pRT11 differ from class I plasmids in that they do not carry HpaI fragment 3000; suggestions for a role played by fragment 3000 in tetracycline resistance will be discussed later. Class II plasmid pRT4 differs from class I plasmid pRT24 in that it is missing HpaI fragment 675 and in that the orientation of HpaI fragment 3000 is reversed. Explanation of the pRT4 resistance phenotype is complex and will be discussed below. Class III includes plasmids pRT22 and pRT29, which specify resistance only to low concentrations of GENE ORGANIZATION IN Tnl0 709 tetracycline (experiment 2). These plasmids differ from class I plasmids in that they are missing both HpaI fragment 3000 and HpaI fragment 675, suggesting that sequences in fragment 675 play some role in resistance.
Tetracycline resistance levels in Table 1 are reported both before and after a 30-min induction period in the presence of 1 ,ug of tetracycline per ml. Resistance in all the recombinant plasmid strains described here is inducible by this treatment, indicating that the regulatory elements for the induction process lie within the 2,025-base pair HpaI fragment of TnlO. It should be noted that the ratio of induced to uninduced EOP50 values may not be an exact reflection of the true induction ratio of those functions responsible for resistance, since measurement of the tetracycline resistance phenotype itself presumably leads to some induction.
Cells containing the R-factor R100 have much higher EOP50 values than pRT61 (a multicopy plasmid carrying the entire TnlO transposon) or the other class I plasmids. This observation can be explained in two ways: (i) R100 encodes functions not found in TnlO but which contribute to tetracycline resistance, or (ii) tetracycline resistance is less well expressed when TnlO is at high copy number. To distinguish these possibilities, the EOP50 values for cells containing a lysogenic X::TnlO phage were determined (Table 1) , with the result that a X::TnlO lysogen is, within error, resistant to the same levels of tetracycline as a cell containing R100. This result favors the hypothesis that the low tetracycline resistance levels found in class I plasmids result from the high copy number ofthese plasmids. Class II plasmids have a resistance phenotype similar to R100; this observation suggests that a TnlO-encoded function that causes lower resistance levels at high copy number maps in HpaI fragment 3000, a fragment that is missing class I plasmids. This hypothesis will be considered further in the Discussion.
Effect of deletions in TnlO on the synthesis of a tetracycline-inducible polypeptide. Many tetracycline-resistant R-factor strains encode a tetracycline-inducible polypeptide (referred to as TET protein) (19, 21 Fig. 3 ). In pRT4, the end of fragment 2025 defined by this site is joined to A DNA sequences in fragment 3000 (Fig. 3) , and so pRT4 encodes a different fusion polypeptide than do pRT22 and pRT29. These plasmids also encode regulatory functions for the induction of both resistance and the tet gene product; thus it would seem that the promoter region and the aminoterminus of the tet gene must be intact in plasmids pRT4, pRT22, and pRT29. If this is the case, the HpaI site in the tet gene lies in the carboxy-terminus of the TET protein, and we can conclude that the direction of tet gene transcription is left to right, as the TnlO map is drawn in Fig. 3 . Yang et al. (35) have reported the synthesis of a 15K tetracycline-inducible polypeptide in R100-containing minicells. We have also observed this polypeptide in R100-containing minicells, but not in minicells containing any of the recombinant plasmids described here. The possibility thus exists that this protein is encoded by regions of R100 outside TnlO. We also observed several other tetracycline-inducible polypeptides, synthesized by both R100 and pRT series recombinant plasmid-containing minicells. These appear in the 15K-25K region of the gel but are present in relatively small amounts. These polypeptides may represent fragments of the 36K protein derived from mild proteolysis or premature translation termination.
RNA polymerase protection of an HincH cleavage site in Tn10: possible location of the tet gene promoter. We have concluded above that the start point of transcription of the tet gene lies in HpaI fragment 2025 because a recombinant plasmid (pRT29) carrying only this fragment shows essentially normal regulation of tetracycline resistance and tet gene product synthesis. RNA polymerase protection of HincII cleavage sites has been observed in several E. coli promoters, e.g., the trp operon promoter (5, 13) and the bacteriophage A PL and PR promoters (1, 2, 23, 25, 34) . As shown by the "protection experiment" presented in Fig. 6 138, 1979 Levy and co-workers (19, 21) have reported the R-factor-directed synthesis of a tetracycline-inducible polypeptide (TET protein) in E. coli minicells. Minicell analysis of a series of recombinant plamids carrying various portions of TnlO (Fig. 5) demonstrates that the TET protein is, as might be expected, encoded by TnlO, as are its regulatory elements.
The recombinant plasmids described in this paper provide a set of TnlO deletions with which it is possible to study the role played by different regions of TnlO in tetracycline resstance and the regulation of its expression. By inspection of the physical structures of these plasmids, the structural gene (tet) encoding the TET protein can be shown to lie within the 2,700-base pairlong region of TnlO c-rried by plasnid pRT11 (see Fig. 3 ). In addition, an Hp,a[ cleavage site within this region lies in the tet gene; this was demonstrated by the observatioon that fusion of different sequences to this site results in alterations in the molecular weight and itability of the tet gene product (Fig. 5) . In all cases these altered tet gene products are inducible. Thus, the regulatory elements are not affocted in the fusion strains and lie wholly within HpaI fragment 2025, as do the promoter and amino-terminus of the tet gene. The HpaI site in tet then lies in the carboxy-terminus of the gene, and the direction of tet transcription is from left to right as the TnlO physical map is drawn in Fig. 1 (30) . R6-5 is a tet plasmid in which an insertion is located within TnlO approximately 1,300 base pairs from one inverted repeat. Tetracycline-resistant derivatives of R6-5 arise by loss of this insertion. This insertion must either be in HindI-HincdI fragment 685 on the "left side" of the transposon, which our data show not to be required for tetracycline resistance, or in HincH fragment 1275 (see restriction map in Fig. 1 ).
I
In Fig. 7 we present schematically a simple model for the location and organization of the tet gene and its regulatory elements. The location of the tet gene and direction of its transcription are shown as stated above. The location of the promoter is inferred from the RNA polymerase "protection experiment" (Fig. 6) . This experiment shows that an Hincd cleavage site in HpaI fragment 2025 lies in a region of in vitro transcription initiation. Recent experiments (L. Wray, R. Jorgensen, and W. Reznikoff, unpublished data) have shown that removal of Hindc fragment 695 and fusion of other Hincd fragments to HincII fragment 1275 affects the level of tetracycline resistance but not the size of the tet gene product. This result strongly suggests that the HincII cleavage site in HpaI fragment 2025 lies in the tet gene promoter, with the result that fusions at this site lead to altered promoter activity.
Mapping the tet promoter at this site is also consistent with the location of the start point of tet translation, which can be approximately determined from the size of the tet gene product. The carboxy-terminus of this protein has been shown here to lie in HpaI fragment 675, probably very near (within 100 base pairs of) the HpaI site, which divides fragments 2025 and 675 (assu1ming that only a small portion of the carboxyterminus of this protein can be replaced with a new amino acid sequence while maintaining the protein's resistance function). The apparent molecular weight of the tet gene product is 36,000 (36K) in Tris-glycine-buffered SDS-polyacrylamide gels (this paper and ref. 34 ) and 50,000 (50K) in a phosphate-buffered SDS-polyacrylamide gel (19) . If Fig. 7 suggests a more precise location (in HincH fragment 695) for the coding region for the "repressor" of Yang et al. (35) . This is consistent with the observation by Reeve (27) that a tet' insertion mutation of R6 (plasmid R6-5) carries an active TET-repressor gene, although more complicated models such as the existence of overlapping tet and repressor genes are not ruled out.
Levy et al. (21) have suggested that the TET protein is responsible for tetracycline resistance, based on observations that the amount of this protein synthesized in minicells seems to be correlated with the level of tetracycline resistance conferred by the particular plasmid encoding it and that tetracycline-sensitive mutants of R222 do not synthesize TET protein. Our observations concerning the effect of TnlO deletions on tetracycline resistance and on the molecular weight and stability of the TET protein are entirely consistent with this view. We have isolated other fusions at the HpaI site in the tet gene through attempts to use pRT29 as an HpaI cloning vehicle for bacteriophage T7 HpaI fragments (while maintaining selection for tetracycline resistance) and for various HpaI fragments with certain selectable characters (e.g., aminoglycoside resistance) (N. Panayotatos, L. Wray, R. Jorgensen, and W. Reznikoff, unpublished data). These fusions also have altered tetracycline resistance levels, supporting a conclusion that the TET protein is both necessary and sufficient for tetracycline resistance.
Taylor et al. (33) have described a copy number mutant of NR1 called ROR12 with a markedly lower level of tetracycline resistance and suggest that this phenotype is a direct result of the higher copy number of ROR12. Recombinant plasmid pRT61, a derivative of the multicopy plasmid ColEl containing the entire TnlO transposon, is resistant to only about one-half the level of tetracycline as is a single-copy A:: TnlO lysogen or R100 (Table 1 ). pRT61 appears to be resitant to higher levels of tetracycline than has been reported for ROR12; however, these two plamsids have not been tested in the same host strain. Taylor et al. (33) have further suggested that the multicopy effect on resistance in ROR12 is due to overproduction of the tet gene repressor by multicopy plasmids. Another possibility is that some TnlO-encoded function interacts directly with the tet gene product. Evidence for the existence of such a TnlO-encoded function is provided by the observed differences between class I and class II plasmids, such as pRT1 and pRT11. Although both of these plasmids encode a wild-type tet gene product, pRT1 is markedly less resistant to tetracycline than is pRT11. The only difference between these plasmids is that HpaI fragment 3000 is not present in pRT11. This suggests that fragment 3000 encodes a function which contributes to the lowered resistance in multicopy plasmids.
